Alejandro Duque
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alejandro Duque has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Jason Moffat
Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Canada
2 shared publications - Sachdev S. Sidhu
School of Pharmacy, University of Waterloo
2 shared publications - Allison M. L. Nixon
Phenomic AI, Toronto, Ontario, Canada
1 shared publication - Angus M. Sinclair
IGM Biosciences, Inc., Mountain View, California
1 shared publication - Catherine Adell O'BRien
Department of Physiology, University of Toronto, Toronto, ON M5S 1A8, Canada; Princess Margaret Cancer Centre, UHN, Toronto, ON M5G 2M9, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada
1 shared publication - Claudia Milena Trujillo Vargas
Grupo de Inmunodeficiencias Primarias, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
1 shared publication
Latest Publications
- 22 June 2025
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 101 (6) , e70037
Percentages of Effector Memory T Cells in Peripheral Blood Associated With Non‐Infectious Comorbidities in Common Variable Immunodeficiency Disorders
Common variable immunodeficiency disorders (CVID) are characterized by hypogammaglobulinemia and increased susceptibility to infections. However, non‐infectious comorbidities (NICM) are also frequent manifestations of the disease. We search for distinctive immunophenotypes in CVID patients with NICM. Data were obtained from the clinical records and laboratory analyses of 42 CVID patients. Descriptive statistics, median comparisons, bivariate and multivariate analysis were performed. Median comparison of the immunological variables among patients with or without NICM revealed significant decreased levels of serum IgG, percentages of naïve CD4+ and CD8+ T cells, total B cells and CD56dim NK cells in peripheral blood from CVID patients with NICM together with an increase in the percentages of effector memory (EM) CD4+ and terminally differentiated effector memory (EMRA) CD8+ T cells. By using logistic regressions, we determined the likelihood of exhibiting blood immunological abnormalities in patients with NICM vs. those without NICM. Finally, discriminant analyses and ROC curves established that percentages of CD4+ EM T cells and CD8+ EMRA T cells > 47.4% and 40.2% from the total CD4+ or CD8+ T cells, respectively, might be associated with NICM in CVID. These differences were also observed in CVID patients with Polyclonal lymphocytic infiltration. These data suggest subpopulations of effector T cells as potential biomarkers of NICM in CVID. Prospective studies are needed to determine the usefulness of our findings in the prognosis of CVID.
- 22 June 2025
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 101 (6) , e70037
Percentages of Effector Memory T Cells in Peripheral Blood Associated With Non‐Infectious Comorbidities in Common Variable Immunodeficiency Disorders
Common variable immunodeficiency disorders (CVID) are characterized by hypogammaglobulinemia and increased susceptibility to infections. However, non‐infectious comorbidities (NICM) are also frequent manifestations of the disease. We search for distinctive immunophenotypes in CVID patients with NICM. Data were obtained from the clinical records and laboratory analyses of 42 CVID patients. Descriptive statistics, median comparisons, bivariate and multivariate analysis were performed. Median comparison of the immunological variables among patients with or without NICM revealed significant decreased levels of serum IgG, percentages of naïve CD4+ and CD8+ T cells, total B cells and CD56dim NK cells in peripheral blood from CVID patients with NICM together with an increase in the percentages of effector memory (EM) CD4+ and terminally differentiated effector memory (EMRA) CD8+ T cells. By using logistic regressions, we determined the likelihood of exhibiting blood immunological abnormalities in patients with NICM vs. those without NICM. Finally, discriminant analyses and ROC curves established that percentages of CD4+ EM T cells and CD8+ EMRA T cells > 47.4% and 40.2% from the total CD4+ or CD8+ T cells, respectively, might be associated with NICM in CVID. These differences were also observed in CVID patients with Polyclonal lymphocytic infiltration. These data suggest subpopulations of effector T cells as potential biomarkers of NICM in CVID. Prospective studies are needed to determine the usefulness of our findings in the prognosis of CVID.
- Open Access
- 20 March 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (14) , 6812-6817
Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies
Aberrant activation of Wnt/β-catenin signaling occurs frequently in cancer. However, therapeutic targeting of this pathway is complicated by the role of Wnt in stem cell maintenance and tissue homeostasis. Here, we evaluated antibodies blocking 6 of the 10 human Wnt/Frizzled (FZD) receptors as potential therapeutics. Crystal structures revealed a common binding site for these monoclonal antibodies (mAbs) on FZD, blocking the interaction with the Wnt palmitoleic acid moiety. However, these mAbs displayed gastrointestinal toxicity or poor plasma exposure in vivo. Structure-guided engineering was used to refine the binding of each mAb for FZD receptors, resulting in antibody variants with improved in vivo tolerability and developability. Importantly, the lead variant mAb significantly inhibited tumor growth in the HPAF-II pancreatic tumor xenograft model. Taken together, our data demonstrate that anti-FZD cancer therapeutic antibodies with broad specificity can be fine-tuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.
- 20 March 2019
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 116 (14) , 6812-6817
Open AccessStructure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies
Aberrant activation of Wnt/β-catenin signaling occurs frequently in cancer. However, therapeutic targeting of this pathway is complicated by the role of Wnt in stem cell maintenance and tissue homeostasis. Here, we evaluated antibodies blocking 6 of the 10 human Wnt/Frizzled (FZD) receptors as potential therapeutics. Crystal structures revealed a common binding site for these monoclonal antibodies (mAbs) on FZD, blocking the interaction with the Wnt palmitoleic acid moiety. However, these mAbs displayed gastrointestinal toxicity or poor plasma exposure in vivo. Structure-guided engineering was used to refine the binding of each mAb for FZD receptors, resulting in antibody variants with improved in vivo tolerability and developability. Importantly, the lead variant mAb significantly inhibited tumor growth in the HPAF-II pancreatic tumor xenograft model. Taken together, our data demonstrate that anti-FZD cancer therapeutic antibodies with broad specificity can be fine-tuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.
- Open Access
- 29 January 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-13
A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations
Cell surface antigen discovery is of great interest for biomedical research both for isolation of rare cell populations and therapeutic targeting. We developed a rapid, cost-effective, fully in vitro technology which facilities the simultaneous target discovery and human antibody generation on the surface of virtually any cell population of interest. We apply our technique to human colorectal cancer-initiating cells (CICs) and identify hundreds of unique human antibodies. We characterized the top three antibody candidates targeting these CICs and identify their protein targets as integrin α7 (ITGA7), HLA-A1 and integrin β6 (ITGB6). We demonstrate that these antibodies can be used to isolate self-renewing colorectal CICs, and that the integrin α7 antibody can prospectively identify glioblastoma brain tumor initiating cells as well as human muscle stem cells. We also demonstrate that genetic ablation of integrin β6 impedes colorectal CIC function. The methodology can be readily applied to other cell populations including stem cells, cancer, or immune cells to facilitate the rapid identification of novel targets and simultaneous generation of potent and specific antibodies with therapeutic potential.
- 29 January 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-13
Open AccessA rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations
Cell surface antigen discovery is of great interest for biomedical research both for isolation of rare cell populations and therapeutic targeting. We developed a rapid, cost-effective, fully in vitro technology which facilities the simultaneous target discovery and human antibody generation on the surface of virtually any cell population of interest. We apply our technique to human colorectal cancer-initiating cells (CICs) and identify hundreds of unique human antibodies. We characterized the top three antibody candidates targeting these CICs and identify their protein targets as integrin α7 (ITGA7), HLA-A1 and integrin β6 (ITGB6). We demonstrate that these antibodies can be used to isolate self-renewing colorectal CICs, and that the integrin α7 antibody can prospectively identify glioblastoma brain tumor initiating cells as well as human muscle stem cells. We also demonstrate that genetic ablation of integrin β6 impedes colorectal CIC function. The methodology can be readily applied to other cell populations including stem cells, cancer, or immune cells to facilitate the rapid identification of novel targets and simultaneous generation of potent and specific antibodies with therapeutic potential.